Want to see NVZMY full AI Analyst Report?
NVZMY Stock Chart & Stats
$70.51
-$0.98(-1.57%)
At close: 4:00 PM EDT
$70.51
-$0.98(-1.57%)
Day’s Range― - ―
52-Week Range$52.70 - $71.98
Previous CloseN/A
Volume30.04K
Average Volume (3M)17.18K
Market Cap
$30.89B
Enterprise Value$32.59K
Total Cash (Recent Filing)$313.47M
Total Debt (Recent Filing)$3.07B
Price to Earnings (P/E)40.8
Beta0.09
Next Earnings
Nov 05, 2026EPS Estimate
0.91Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)1.39
Shares Outstanding414,555,050
10 Day Avg. Volume1,277
30 Day Avg. Volume17,175
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)15.45
Price to Sales (P/S)40.34
P/FCF Ratio223.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.39
Revenue Forecast (FY)$5.20B
Bulls Say, Bears Say
Bulls Say
Organic GrowthBroad-based organic growth and upgraded guidance indicate continued customer adoption across food, household care, agriculture and industrial markets. Volume-led expansion, pricing and sales synergies support a durable revenue trajectory.
Margin And Innovation StrengthStrong margins and ongoing product launches support Novonesis’s ability to monetize differentiated biosolutions. Sustained R&D investment and innovation can reinforce customer retention, pricing power and long-term competitiveness.
Cash GenerationSubstantial operating and free cash flow gives Novonesis capacity to fund research, manufacturing expansion, acquisitions and shareholder returns. Strong cash generation also provides flexibility when reported earnings are affected by non-cash or timing items.
Bears Say
Earnings VolatilityThe divergence between strong operating performance and a TTM net loss reduces confidence in earnings quality and repeatability. Continued volatility could limit the reliability of profitability as a funding source for long-term growth.
Leverage InconsistencyThe sharp change in reported leverage makes the balance-sheet profile harder to assess and raises execution risk around financing and integration. Although TTM leverage is conservative, investors must monitor whether debt levels remain controlled.
Uneven End-Market DemandSlower Human Health growth and weakness in Tech and Plant show that demand is not uniform across the portfolio. Persistent softness in these markets could dilute group growth and make the upgraded outlook more dependent on stronger divisions.
Novonesis News
NVZMY FAQ
What was Novonesis’s price range in the past 12 months?
Novonesis lowest stock price was $52.70 and its highest was $71.98 in the past 12 months.
What is Novonesis’s market cap?
Novonesis’s market cap is $30.89B.
When is Novonesis’s upcoming earnings report date?
Novonesis’s upcoming earnings report date is Nov 05, 2026 which is in 48 days.
How were Novonesis’s earnings last quarter?
Novonesis released its earnings results on Aug 19, 2026. The company reported $0.443 earnings per share for the quarter, missing the consensus estimate of $0.626 by -$0.183.
Is Novonesis overvalued?
According to Wall Street analysts Novonesis’s price is currently Overvalued.
Does Novonesis pay dividends?
Novonesis pays a Semiannually dividend of $0.057 which represents an annual dividend yield of 0.24%. See more information on Novonesis dividends here
What is Novonesis’s EPS estimate?
Novonesis’s EPS estimate is 0.91.
How many shares outstanding does Novonesis have?
Novonesis has 414,555,050 shares outstanding.
What happened to Novonesis’s price movement after its last earnings report?
Novonesis reported an EPS of $0.443 in its last earnings report, missing expectations of $0.626. Following the earnings report the stock price went up 0.022%.
Which hedge fund is a major shareholder of Novonesis?
Currently, no hedge funds are holding shares in NVZMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novonesis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.19%
12-Months-Change
Fundamentals
Return on Equity
0.24%
Trailing 12-Months
Asset Growth
-1.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novonesis
Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region. The company's broad range of products caters to numerous sectors: Food and Beverages: Supplying ingredients and processing aids for baking, a variety of beverages, dairy production, starch modification, and protein applications. Household Care: Delivering specialized formulations for laundry, dishwashing, and professional cleaning solutions. Agriculture: Providing innovations for crop cultivation, animal health and nutrition, alongside bioyield and biocontrol products for plant growth. Bioenergy and Industrial Processing: Offering critical components for grain and technical processing, encompassing liquefaction, saccharification, fermentation, fiber conversion, and biomass transformation. Textiles: Featuring technologies for biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing. Pulp and Paper: Enhancing processes through fiber modification, bleach boosting, deposit control, starch modification, and deinking agents. Leather Production: Furnishing treatments for acid bating, area expansion, general bating, degreasing, soaking, and unhairing/liming stages. Water and Waste Management: Contributing with bioaugmentation strategies, optimization of biogas production, and sludge management. Pharmaceuticals: Supplying specialized lipases (both free and immobilized), proteases for biocatalysis, and rTrypsin vital for cell culture applications. Furthermore, Novozymes provides offerings related to human health and various protein-based products. Founded in 1925, Novozymes A/S is headquartered in Bagsvaerd, Denmark.
NVZMY Company Deck
NVZMY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong, broad-based organic growth, margin expansion, robust cash generation and clear capital allocation actions (EUR 1bn buyback, bolt‑on M&A, capacity investments). These positives were balanced by notable headwinds — currency effects, country exits, a softer Human Health outlook, one-off inventory timing and a temporary elevation in CapEx and operating costs. On balance the company appears to be executing well and is confident in sustainable demand and returns, but investors should monitor H2 effects from tariff reimbursements, the normalization of the Q1 inventory benefit and the near-term impact of elevated CapEx.View all NVZMY earnings summariesNVZMY Revenue Breakdown
28.53% Household Care
24.83% Bioenergy
22.07% Food, Beverages & Human Health
12.82% Grain & Tech Processing
11.75% Agriculture & Animal Health
Technical Analysis
Eastman Chemical
―
PPG Industries
―
Sherwin-Williams Company
―
Stepan Company
―
Element Solutions
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors